drugset / Trial / NCT04705896
Albumin To Enhance Recovery After Acute Kidney Injury
Phase 4
Recruiting
856 enrolled
Ottawa Hospital Research Institute
Canadian Blood Services · collabCanadian Institutes of Health Research (CIHR) · collabHéma-Québec · collabThe Kidney Foundation of Canada · collabThe Ottawa Hospital Academic Medical Organization (TOHAMO) Innovation Fund Grant. · collabThe Physicians' Services Incorporated Foundation · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Study objectives: To determine whether, in critically ill patients with Acute Kidney Injury requiring renal replacement therapy (AKI-RRT), randomization to receive intravenous hyperoncotic albumin 20-25% (100 mL X two doses) compared to control/placebo normal saline boluses (100 mL X two doses) given during RRT sessions, leads to: 1. An increase in organ support-free days (primary outcome) at 28 days following randomization; and 2. An increase in RRT-free days (principal secondary outcome) at 28 days following randomization.
Timeline
- Start
- 2023-11-02
- Primary completion
- 2025-08-28
- Completion
- 2025-10-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Albumin | Protein / enzyme biologic | 100 ml | Intravenous |